AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 13:00:00 CEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
7 Days Left: LiberNovo Maxis, Big & Tall's Ultimate Seat9.6.2026 11:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 9, 2026 / Built from the ground up for larger frames, the Maxis series launches June 16 starting at €829, with super early bird savings up to 48% off MSRP. For Big & Tall buyers, the ergonomic chair search usually starts with the spec sheet. Most chairs in this segment are built on the standard ergonomic envelope and scaled up, not designed for a larger body in the first place. LiberNovo's Maxis series, launching June 16, is the brand's first line engineered from the start for that body. It ships in three configurations alongside two new additions to the LiberNovo Omni family. A larger geometry, by design Standard ergonomic chairs are sized for a body that runs around 5'9" and 170 pounds. Maxis is sized for the bodies that don't fit those numbers. Its 52 cm seat extends fully under the thigh, so the front edge won't cut off circulation by mid-afternoon. The frame is BIFMA-certified to 181 kg (399 lb), supported by a die-cast aluminum alloy base th
Family Online Safety Institute Hosts 2026 European Forum in Brussels, Convening Global Leaders to Find Common Ground on Online Safety9.6.2026 07:30:00 CEST | Press release
New Research on Australia's Social Media Ban Released Alongside Day of Sessions with OECD, Ofcom, and Global Industry Leaders BRUSSELS, BE / ACCESS Newswire / June 9, 2026 / The Family Online Safety Institute (FOSI) is pleased to host its 2026 European Forum, "Finding Common Ground," taking place today at Google's offices in Brussels, Belgium. This Forum brings together policymakers, regulators, researchers, industry leaders, and civil society organizations from across Europe and beyond to explore one central question: how can we find common ground on online safety? Throughout the day, attendees will explore developments in online safety regulation, emerging research on children's digital wellbeing, the growing role of AI in the lives of families, and realistic approaches to creating safer digital experiences for young people and families. Featured sessions include a discussion with representatives from the OECD, Ofcom, and Arcom, ATKM, and Belgium's Institute for Postal Services and T
Three Polaris Projects in Mexico Selected Under the Mixed Development Program9.6.2026 01:40:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 8, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announced that Mexico's Secretary of Energy (Secretaría de Energía, "SENER"), and the Federal Electricity Commission (Comisión Federal de Electricidad, "CFE") have completed the first national competitive selection process under the CFE Mixed Development Program. The process was launched through a Request for Proposals ("RfP") issued in February 2026, with submitted projects evaluated in accordance with the Guidelines for Mixed Development Programs published by SENER in January 2026. On June 5, 2026, CFE and SENER announced that the final award volume exceeded the original target, with approximately 8,000 MW of projects selected for advancement under the program. As part of this award process, Polaris is pleased to announce that all three Polaris-owned projects submitted under the Mixed Development Program have been selected to advance to the final contract negotiation st
GA-ASI Announces Investments in Six Dutch Companies8.6.2026 18:00:00 CEST | Press release
New Slate of Business Partnerships Established Following the Last Blue Magic Netherlands Event SAN DIEGO, CA / ACCESS Newswire / June 8, 2026 / General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative. These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities. Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom